Breakthrough study finds weight loss drugs could bring added health benefits for millions
A study has revealed new findings about GLP-1 drugs
A new breakthrough study has found that weight loss drugs could potentially bring added health benefits for millions of people.
This was revealed after new research looked into an unexpected way that the medication could be boosting your health.
Millions of people are now taking the likes of Ozempic and Mounjaro after they became popular methods to tackle obesity.
Plenty of celebrities have also jumped on the bandwagon with the likes of Elon Musk, Oprah Winfrey and Kelly Clarkson openly admitting to taking these types of medication.
Advert
Now the study, which was conducted by a team of researchers, looked into how GLP-1 drugs could be doing more than assisting weight loss.
With their findings, the experts now believe that the medication could also reduce the risk of heart patients being hospitalized or dying early by half.
This is because weight loss drugs have been found to offer users ‘dramatic benefits’ to heart patients by significantly lowering the risk of becoming seriously ill, according to a report by the Guardian.
The shock findings were presented at the 2025 European Society of Cardiology Congress in Madrid, Spain, last month.
How did the study work?
Researchers conducted trials involving patients with a type of heart failure called heart failure with preserved ejection fraction (HFpEF), and treated them with either GLP-1 receptor agonists or a placebo.
A total of 54 worsening heart failure events were reported among 1,914 patients receiving GLP1-receptor antagonist treatment, compared to 86 events among 1,829 patients receiving placebo.
In short, it revealed that tirzepatide cut the risk of hospitalisation for heart failure or death from any cause by 58 percent, while those taking semaglutide were 42 percent less likely.
Author of the groundbreaking study, which was the largest of its kind, Dr Nils Krüger, said: “Despite the widespread morbidity and mortality burden of HFpEF, current treatment options are limited.
"Both semaglutide and tirzepatide are well known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and type 2 diabetes by reducing adverse heart failure outcomes."
She added: “Our findings show that in the future, GLP-1 targeting medications could provide a much-needed treatment option for patients with heart failure.”
Meanwhile, Dr Carlos Aguiar, the vice-president of the European Society of Cardiology and a renowned expert in heart failure, has praised the findings.
He said: “What this shows is that there is a benefit in using one of these two agents, semaglutide or tirzepatide, to reduce the risk of hospitalisation for heart failure or all-cause mortality.
“We thought that we actually might not really find a treatment that would work well for a significant proportion of these patients, and what’s been a good surprise is that these drugs that are working through weight loss, but possibly through other effects that go beyond weight loss, are potentially reducing the rates of hospitalisation and mortality in patients with heart failure."